NCBI Home Page NCBI Site Search page NCBI Guide that lists and describes the NCBI resources
Conserved domains on  [gi|221379089|ref|NP_650273|]
View 

uncharacterized protein Dmel_CG8773 [Drosophila melanogaster]

Protein Classification

Graphical summary

 Zoom to residue level

show extra options »

Show site features     Horizontal zoom: ×

List of domain hits

Name Accession Description Interval E-value
M1_APN-Q_like cd09601
Peptidase M1 aminopeptidase N catalytic domain family which includes aminopeptidase N (APN), ...
130-573 0e+00

Peptidase M1 aminopeptidase N catalytic domain family which includes aminopeptidase N (APN), aminopeptidase Q (APQ), tricorn interacting factor F3, and endoplasmic reticulum aminopeptidase 1 (ERAP1); This M1 peptidase family includes eukaryotic and bacterial members: the catalytic domains of aminopeptidase N (APN), aminopeptidase Q (APQ, laeverin), endoplasmic reticulum aminopeptidase 1 (ERAP1) as well as tricorn interacting factor F3. Aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease, preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is considered a marker of differentiation since it is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. ERAP1, also known as endoplasmic reticulum aminopeptidase associated with antigen processing (ERAAP), adipocyte derived leucine aminopeptidase (A-LAP), or aminopeptidase regulating tumor necrosis factor receptor I (THFRI) shedding (ARTS-1), associates with the closely related ER aminopeptidase ERAP2, for the final trimming of peptides within the ER for presentation by MHC class I molecules. ERAP1 is associated with ankylosing spondylitis (AS), an inflammatory arthritis that predominantly affects the spine. ERAP1 also aids in the shedding of membrane-bound cytokine receptors. The tricorn interacting factor F3, together with factors F1 and F2, degrades the tricorn protease products, producing free amino acids, thus completing the proteasomal degradation pathway. F3 is homologous to F2, but not F1, and shows a strong preference for glutamate in the P1' position. APQ, also known as laeverin, is specifically expressed in human embryo-derived extravillous trophoblasts (EVTs) that invade the uterus during early placentation. It cleaves the N-terminal amino acid of various peptides such as angiotensin III, endokinin C, and kisspeptin-10, all expressed in the placenta in large quantities. APN is a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs are also putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


:

Pssm-ID: 341064 [Multi-domain]  Cd Length: 442  Bit Score: 636.54  E-value: 0e+00
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089 130 THYDLYLFPNIETGEFSGQETITITVEEATDQIVLHSLNLNISSVSIMNTGSDTLEILETTVDAVREFLIFQLNEPLTKG 209
Cdd:cd09601    1 LHYDLTLTPDLENFTFSGSVTITLEVLEPTDTIVLHAKDLTITSASLTLKGGSGIIEVTVVTDEETEFLTITLDETLPPG 80
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089 210 RTVRLHIGFEGSMANKIVGLYSSSYVKEDETRKWIATSKFEPTYARQAFPCFDEPALKAEFTITLVHPsgEDYHALSNMN 289
Cdd:cd09601   81 ENYTLSIEFTGKLNDDLRGFYRSSYTDEDGETRYLAATQFEPTDARRAFPCFDEPAFKATFDITITHP--KGYTALSNMP 158
                        170       180       190       200       210       220       230       240
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089 290 -VDSSVSQGAFQEVTFAKSVPMSTYLACFIVSDFAYKQvSIDTKGIgetfSMSVYATPEQLDKVDLAVTIGKGVIEYYID 368
Cdd:cd09601  159 pVESTELEDGWKTTTFETTPPMSTYLVAFVVGDFEYIE-STTKSGV----PVRVYARPGKIEQGDFALEVAPKILDFYED 233
                        250       260       270       280       290       300       310       320
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089 369 YFQIAYPLPKLDMAAIPDFVSGAMEHWGLVTYRETSLLYDEATSSATNKQRIASVIAHEFAHMWFGNLVTMNWWNDLWLN 448
Cdd:cd09601  234 YFGIPYPLPKLDLVAIPDFAAGAMENWGLITYRETALLYDPKTSSASDKQRVAEVIAHELAHQWFGNLVTMKWWDDLWLN 313
                        330       340       350       360       370       380       390       400
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089 449 EGFASFVEYLGVDAVYPEWKMRDQFTVSTLHSVLTLDGTLGSHPIIQTVENPDQITEIFDTITYSKGSSLVRMLEDFLGE 528
Cdd:cd09601  314 EGFATYMEYLAVDKLFPEWNMWDQFVVDELQSALELDSLASSHPIEVPVESPSEISEIFDAISYSKGASVLRMLENFLGE 393
                        410       420       430       440
                 ....*....|....*....|....*....|....*....|....*...
gi 221379089 529 TTFRQAVTNYLNEYKYSTAETGNFFTEIDK---LELGYNVTEIMLTWT 573
Cdd:cd09601  394 EVFRKGLRKYLKKHAYGNATTDDLWEALQEasgESKPLDVKEIMDSWT 441
ERAP1_C pfam11838
ERAP1-like C-terminal domain; This large domain is composed of 16 alpha helices organized as 8 ...
654-973 1.58e-97

ERAP1-like C-terminal domain; This large domain is composed of 16 alpha helices organized as 8 HEAT-like repeats. This domain forms a concave face that faces towards the active site of the peptidase.


:

Pssm-ID: 463368 [Multi-domain]  Cd Length: 316  Bit Score: 309.98  E-value: 1.58e-97
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089  654 WIKFNADQVGYYRVNYDTDLWNDLADQLvvQPSAFGSVDRAHLLNDAFALADSTQLPYATAFELTRYLDKETDYVPWSVA 733
Cdd:pfam11838   1 WVKLNADDTGYYRVNYDPESLAALLEQL--LSKVLSPLDRAGLIDDAFALARAGELSTSDALDLVLAYLNETDYVVWSAA 78
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089  734 ASRLTSLKRTLYYTSTYAKYKKYATALIEPIYTALTWT--VGEDHLDNRLRVTALSAACSLGLESCLTEAGEQFNAWLAK 811
Cdd:pfam11838  79 LSQLSTLRSLLSADPEYEALKAFLRKLLSPLAEKLGWEapPGESHLDRQLRALLLSAACSAGDPECVAEAKKLFDAWLDG 158
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089  812 PEDRPkADVRETVYYYGIQSvGSQEDWDAVWELFVNESDASEKSKLMYGLSAIQIPWILQRYIDLAWNEEYVRGQDYFTC 891
Cdd:pfam11838 159 DDAIP-PDLRWAVYCAAVAN-GGEAEWDALLERYRDTTSPSEKERALRALAATPDPELLQRALELALDSDEVRNQDLRAV 236
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089  892 LTYISANPVGESLVWDYVRENWQRLVDRFGLNErYLGNLIPSITARFSTQTKLEEMEQFFAKYPEAGAGTAARvRALETV 971
Cdd:pfam11838 237 IAGLASNPAGRDLAWDFVKENWDALVKRLGGGS-SLGRLVKGLTPSFSTEEELDEVEAFFADKDTPGLRRALA-QALETI 314

                  ..
gi 221379089  972 KN 973
Cdd:pfam11838 315 RR 316
KLF9_13_N-like super family cl41730
Kruppel-like factor (KLF) 9, KLF13, KLF14, KLF16, and similar proteins; Kruppel/Krueppel-like ...
17-118 6.04e-04

Kruppel-like factor (KLF) 9, KLF13, KLF14, KLF16, and similar proteins; Kruppel/Krueppel-like transcription factors (KLFs) belong to a family of proteins, called the Specificity Protein (SP)/KLF family, characterized by a C-terminal DNA-binding domain of 81 amino acids consisting of three Kruppel-like C2H2 zinc fingers. These factors bind to a loose consensus motif, namely NNRCRCCYY (where N is any nucleotide; R is A/G, and Y is C/T), such as the recurring motifs in GC and GT boxes (5'-GGGGCGGGG-3' and 5-GGTGTGGGG-3') that are present in promoters and more distal regulatory elements of mammalian genes. Members of the KLF family can act as activators or repressors of transcription depending on cell and promoter context. KLFs regulate various cellular functions, such as proliferation, differentiation, and apoptosis, as well as the development and homeostasis of several types of tissue. KLF9, KLF10, KLF11, KLF13, KLF14, and KLF16 share a conserved alpha-helical motif AA/VXXL that mediates their binding to Sin3A and their activities as transcriptional repressors. In addition to the C-terminal DNA-binding domain, each KLF also has a unique N-terminal activation/repression domain that confers specificity and allows it to bind specifically to a certain partner, leading to distinct activities in vivo. This model represents the related N-terminal domains of KLF9, KLF13, KLF14, KLF16, and similar proteins.


The actual alignment was detected with superfamily member cd21975:

Pssm-ID: 425361 [Multi-domain]  Cd Length: 163  Bit Score: 41.60  E-value: 6.04e-04
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089  17 TAFTVSTIVLAvqkANLKSDLRDAQEKLDLLEAGyTSTAAPTTASTANPGSTA--SPGSTAEPGSTAEPGSTAEPGSTAS 94
Cdd:cd21975   62 GLVTAAPHLLA---ANVLAPLRGPSVEGSSLESG-DADMGSDSDVAPASGAAAstSPESSSDAASSPSPLSLLHPGEAGL 137
                         90       100
                 ....*....|....*....|....
gi 221379089  95 PGSTVTPGSTASTSEPGTTASPEK 118
Cdd:cd21975  138 EPERPRPRVRRGVRRRGVTPAAKR 161
 
Name Accession Description Interval E-value
M1_APN-Q_like cd09601
Peptidase M1 aminopeptidase N catalytic domain family which includes aminopeptidase N (APN), ...
130-573 0e+00

Peptidase M1 aminopeptidase N catalytic domain family which includes aminopeptidase N (APN), aminopeptidase Q (APQ), tricorn interacting factor F3, and endoplasmic reticulum aminopeptidase 1 (ERAP1); This M1 peptidase family includes eukaryotic and bacterial members: the catalytic domains of aminopeptidase N (APN), aminopeptidase Q (APQ, laeverin), endoplasmic reticulum aminopeptidase 1 (ERAP1) as well as tricorn interacting factor F3. Aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease, preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is considered a marker of differentiation since it is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. ERAP1, also known as endoplasmic reticulum aminopeptidase associated with antigen processing (ERAAP), adipocyte derived leucine aminopeptidase (A-LAP), or aminopeptidase regulating tumor necrosis factor receptor I (THFRI) shedding (ARTS-1), associates with the closely related ER aminopeptidase ERAP2, for the final trimming of peptides within the ER for presentation by MHC class I molecules. ERAP1 is associated with ankylosing spondylitis (AS), an inflammatory arthritis that predominantly affects the spine. ERAP1 also aids in the shedding of membrane-bound cytokine receptors. The tricorn interacting factor F3, together with factors F1 and F2, degrades the tricorn protease products, producing free amino acids, thus completing the proteasomal degradation pathway. F3 is homologous to F2, but not F1, and shows a strong preference for glutamate in the P1' position. APQ, also known as laeverin, is specifically expressed in human embryo-derived extravillous trophoblasts (EVTs) that invade the uterus during early placentation. It cleaves the N-terminal amino acid of various peptides such as angiotensin III, endokinin C, and kisspeptin-10, all expressed in the placenta in large quantities. APN is a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs are also putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341064 [Multi-domain]  Cd Length: 442  Bit Score: 636.54  E-value: 0e+00
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089 130 THYDLYLFPNIETGEFSGQETITITVEEATDQIVLHSLNLNISSVSIMNTGSDTLEILETTVDAVREFLIFQLNEPLTKG 209
Cdd:cd09601    1 LHYDLTLTPDLENFTFSGSVTITLEVLEPTDTIVLHAKDLTITSASLTLKGGSGIIEVTVVTDEETEFLTITLDETLPPG 80
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089 210 RTVRLHIGFEGSMANKIVGLYSSSYVKEDETRKWIATSKFEPTYARQAFPCFDEPALKAEFTITLVHPsgEDYHALSNMN 289
Cdd:cd09601   81 ENYTLSIEFTGKLNDDLRGFYRSSYTDEDGETRYLAATQFEPTDARRAFPCFDEPAFKATFDITITHP--KGYTALSNMP 158
                        170       180       190       200       210       220       230       240
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089 290 -VDSSVSQGAFQEVTFAKSVPMSTYLACFIVSDFAYKQvSIDTKGIgetfSMSVYATPEQLDKVDLAVTIGKGVIEYYID 368
Cdd:cd09601  159 pVESTELEDGWKTTTFETTPPMSTYLVAFVVGDFEYIE-STTKSGV----PVRVYARPGKIEQGDFALEVAPKILDFYED 233
                        250       260       270       280       290       300       310       320
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089 369 YFQIAYPLPKLDMAAIPDFVSGAMEHWGLVTYRETSLLYDEATSSATNKQRIASVIAHEFAHMWFGNLVTMNWWNDLWLN 448
Cdd:cd09601  234 YFGIPYPLPKLDLVAIPDFAAGAMENWGLITYRETALLYDPKTSSASDKQRVAEVIAHELAHQWFGNLVTMKWWDDLWLN 313
                        330       340       350       360       370       380       390       400
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089 449 EGFASFVEYLGVDAVYPEWKMRDQFTVSTLHSVLTLDGTLGSHPIIQTVENPDQITEIFDTITYSKGSSLVRMLEDFLGE 528
Cdd:cd09601  314 EGFATYMEYLAVDKLFPEWNMWDQFVVDELQSALELDSLASSHPIEVPVESPSEISEIFDAISYSKGASVLRMLENFLGE 393
                        410       420       430       440
                 ....*....|....*....|....*....|....*....|....*...
gi 221379089 529 TTFRQAVTNYLNEYKYSTAETGNFFTEIDK---LELGYNVTEIMLTWT 573
Cdd:cd09601  394 EVFRKGLRKYLKKHAYGNATTDDLWEALQEasgESKPLDVKEIMDSWT 441
PepN COG0308
Aminopeptidase N, contains DUF3458 domain [Amino acid transport and metabolism];
120-715 4.06e-120

Aminopeptidase N, contains DUF3458 domain [Amino acid transport and metabolism];


Pssm-ID: 440077 [Multi-domain]  Cd Length: 609  Bit Score: 380.14  E-value: 4.06e-120
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089 120 DYRlPGTLKPTHYDLYLFPNIETGEFSGQETITITVEEA-TDQIVLHSLNLNISSVSIMNTgsdtleilETTVDAVREFL 198
Cdd:COG0308    9 AYR-PPGYDVTHYDLDLDLDPATTRLSGTATITFTATEApLDSLVLDLKGLEVTSVTVDGK--------PLDFTRDGERL 79
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089 199 IFQLNEPLTKGRTVRLHIGFEGSMANKIVGLYSSSYVKEDETrkWIATSkFEPTYARQAFPCFDEPALKAEFTITLVHPs 278
Cdd:COG0308   80 TITLPKPLAPGETFTLEIEYSGKPSNGGEGLYRSGDPPDGPP--YLYTQ-CEPEGARRWFPCFDHPDDKATFTLTVTVP- 155
                        170       180       190       200       210       220       230       240
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089 279 gEDYHALSNMN-VDSSVSQGAFQEVTFAKSVPMSTYLACFIVSDFAYKQVSIdTKGIgetfSMSVYATPEQLDKVDLAVT 357
Cdd:COG0308  156 -AGWVAVSNGNlVSETELGDGRTTWHWADTQPIPTYLFALAAGDYAVVEDTF-ASGV----PLRVYVRPGLADKAKEAFE 229
                        250       260       270       280       290       300       310       320
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089 358 IGKGVIEYYIDYFQIAYPLPKLDMAAIPDFVSGAMEHWGLVTYRETSLLYDEATSSatNKQRIASVIAHEFAHMWFGNLV 437
Cdd:COG0308  230 STKRMLDFFEELFGVPYPFDKYDQVAVPDFNFGAMENQGLVTFGEKVLADETATDA--DYERRESVIAHELAHQWFGNLV 307
                        330       340       350       360       370       380       390       400
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089 438 TMNWWNDLWLNEGFASFVEYLGVDAVYPE--WKMRDQFTVSTLHsvLTLDGTLGSHPIIqtVENPDQITEIFDTITYSKG 515
Cdd:COG0308  308 TCADWDDLWLNEGFATYMEQLFSEDLYGKdaADRIFVGALRSYA--FAEDAGPNAHPIR--PDDYPEIENFFDGIVYEKG 383
                        410       420       430       440       450       460       470       480
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089 516 SSLVRMLEDFLGETTFRQAVTNYLNEYKYSTAETGNFFTEIDKlELGYNVTEIMLTWTVQMGLPVVTIEKVSDTEYK--- 592
Cdd:COG0308  384 ALVLHMLRTLLGDEAFRAGLRLYFARHAGGNATTEDFLAALEE-ASGRDLSAFFDQWLYQAGLPTLEVEYEYDADGKvtl 462
                        490       500       510       520       530       540       550       560
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089 593 -LTQKRFlsnpndydadhepseFNYRWSIPITYFTSSDSVVQRLWFYHDQSEITVTVPAAVEWIKFNADQVGYYRVNYDT 671
Cdd:COG0308  463 tLRQTPP---------------RPHPFHIPLEVGLLGGKLTARTVLLDGEQTELVAKPDPVLLLRLDDELAFLLAHDSDP 527
                        570       580       590       600       610
                 ....*....|....*....|....*....|....*....|....*....|..
gi 221379089 672 --------DLWNDLADQLVVQPSAFGSVDRAhLLNDAFALADSTQLPYATAF 715
Cdd:COG0308  528 fnrwealqALWRDGEADYLDALRALADTDPA-VRAEALALLGSDQLALARAA 578
Peptidase_M1 pfam01433
Peptidase family M1 domain; Members of this family are aminopeptidases. The members differ ...
355-572 3.83e-101

Peptidase family M1 domain; Members of this family are aminopeptidases. The members differ widely in specificity, hydrolysing acidic, basic or neutral N-terminal residues. This family includes leukotriene-A4 hydrolase, this enzyme also has an aminopeptidase activity.


Pssm-ID: 426262 [Multi-domain]  Cd Length: 219  Bit Score: 315.77  E-value: 3.83e-101
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089  355 AVTIGKGVIEYYIDYFQIAYPLPKLDMAAIPDFVSGAMEHWGLVTYRETSLLYDEATSSATNKQRIASVIAHEFAHMWFG 434
Cdd:pfam01433   2 ALEITVKLLEFYEDYFNIPYPLPKYDLVALPDFSAGAMENWGLITYRETLLLYDPGNSSTSDKQRVASVIAHELAHQWFG 81
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089  435 NLVTMNWWNDLWLNEGFASFVEYLGVDAVYPEWKMRDQFTVSTLHSVLTLDGTLGSHPIIQTVENPDQITEIFDTITYSK 514
Cdd:pfam01433  82 NLVTMKWWDDLWLNEGFATYMEYLGTDALFPEWNIWEQFLLDEVQNAMARDALDSSHPITQNVNDPSEIDDIFDAIPYEK 161
                         170       180       190       200       210
                  ....*....|....*....|....*....|....*....|....*....|....*...
gi 221379089  515 GSSLVRMLEDFLGETTFRQAVTNYLNEYKYSTAETGNFFTEIDKLELGYNVTEIMLTW 572
Cdd:pfam01433 162 GASVLRMLETLLGEEVFQKGLRSYLKKFQYGNATTEDLWDALSEASGPLDVDSFMDTW 219
ERAP1_C pfam11838
ERAP1-like C-terminal domain; This large domain is composed of 16 alpha helices organized as 8 ...
654-973 1.58e-97

ERAP1-like C-terminal domain; This large domain is composed of 16 alpha helices organized as 8 HEAT-like repeats. This domain forms a concave face that faces towards the active site of the peptidase.


Pssm-ID: 463368 [Multi-domain]  Cd Length: 316  Bit Score: 309.98  E-value: 1.58e-97
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089  654 WIKFNADQVGYYRVNYDTDLWNDLADQLvvQPSAFGSVDRAHLLNDAFALADSTQLPYATAFELTRYLDKETDYVPWSVA 733
Cdd:pfam11838   1 WVKLNADDTGYYRVNYDPESLAALLEQL--LSKVLSPLDRAGLIDDAFALARAGELSTSDALDLVLAYLNETDYVVWSAA 78
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089  734 ASRLTSLKRTLYYTSTYAKYKKYATALIEPIYTALTWT--VGEDHLDNRLRVTALSAACSLGLESCLTEAGEQFNAWLAK 811
Cdd:pfam11838  79 LSQLSTLRSLLSADPEYEALKAFLRKLLSPLAEKLGWEapPGESHLDRQLRALLLSAACSAGDPECVAEAKKLFDAWLDG 158
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089  812 PEDRPkADVRETVYYYGIQSvGSQEDWDAVWELFVNESDASEKSKLMYGLSAIQIPWILQRYIDLAWNEEYVRGQDYFTC 891
Cdd:pfam11838 159 DDAIP-PDLRWAVYCAAVAN-GGEAEWDALLERYRDTTSPSEKERALRALAATPDPELLQRALELALDSDEVRNQDLRAV 236
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089  892 LTYISANPVGESLVWDYVRENWQRLVDRFGLNErYLGNLIPSITARFSTQTKLEEMEQFFAKYPEAGAGTAARvRALETV 971
Cdd:pfam11838 237 IAGLASNPAGRDLAWDFVKENWDALVKRLGGGS-SLGRLVKGLTPSFSTEEELDEVEAFFADKDTPGLRRALA-QALETI 314

                  ..
gi 221379089  972 KN 973
Cdd:pfam11838 315 RR 316
pepN_strep_liv TIGR02412
aminopeptidase N, Streptomyces lividans type; This family is a subset of the members of the ...
247-558 7.82e-62

aminopeptidase N, Streptomyces lividans type; This family is a subset of the members of the zinc metallopeptidase family M1 (pfam01433), with a single member characterized in Streptomyces lividans 66 and designated aminopeptidase N. The spectrum of activity may differ somewhat from the aminopeptidase N clade of E. coli and most other Proteobacteria, well separated phylogenetically within the M1 family. The M1 family also includes leukotriene A-4 hydrolase/aminopeptidase (with a bifunctional active site).


Pssm-ID: 274121 [Multi-domain]  Cd Length: 831  Bit Score: 226.21  E-value: 7.82e-62
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089  247 SKFEPTYARQAFPCFDEPALKAEFTITLVHPsgEDYHALSNMNVDSSVSQGAFQEVTFAKSVPMSTYLACFIVSDFaykq 326
Cdd:TIGR02412 122 TQFEPADARRVFAVFDQPDLKANFKFSVKAP--EDWTVISNSRETDVTPEPADRRWEFPETPKLSTYLTAVAAGPY---- 195
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089  327 VSIDTKGigETFSMSVYATP---EQLDKvDLAVTIGKGVIEYYIDYFQIAYPLPKLDMAAIPDFVSGAMEHWGLVTYRET 403
Cdd:TIGR02412 196 HSVQDES--RSYPLGIYARRslaQYLDA-DAIFTITRQGLAFFHRKFGYPYPFKKYDQIFVPEFNAGAMENAGCVTFAEN 272
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089  404 SLLYDEATSSAtnKQRIASVIAHEFAHMWFGNLVTMNWWNDLWLNEGFASFVEYLGVDAV--YPE-WKmrdQFTVSTLHS 480
Cdd:TIGR02412 273 FLHRAEATRAE--KENRAGVILHEMAHMWFGDLVTMRWWNDLWLNESFAEYMGTLASAEAteYTDaWT---TFAAQGKQW 347
                         250       260       270       280       290       300       310
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*...
gi 221379089  481 VLTLDGTLGSHPIIQTVENPDQITEIFDTITYSKGSSLVRMLEDFLGETTFRQAVTNYLNEYKYSTAETGNFFTEIDK 558
Cdd:TIGR02412 348 AYEADQLPTTHPIVADVADLADALSNFDGITYAKGASVLKQLVAWVGEEAFFAGVNAYFKRHAFGNATLDDLIDSLAK 425
pepN PRK14015
aminopeptidase N; Provisional
364-594 1.69e-15

aminopeptidase N; Provisional


Pssm-ID: 237585 [Multi-domain]  Cd Length: 875  Bit Score: 81.33  E-value: 1.69e-15
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089 364 EYYIDYFQIAyplpkldmaAIPDFVSGAMEHWGL-------VtyretslLYDEATssATNK--QRIASVIAHEFAHMWFG 434
Cdd:PRK14015 249 EYDLDIFMIV---------AVDDFNMGAMENKGLnifnskyV-------LADPET--ATDAdyERIESVIAHEYFHNWTG 310
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089 435 NLVTMNWWNDLWLNEGFASFveylgvdavypewkmRDQ-FTvSTLHS--------VLTLD--------GTLgSHPIiqtv 497
Cdd:PRK14015 311 NRVTCRDWFQLSLKEGLTVF---------------RDQeFS-ADLGSravkriedVRVLRaaqfaedaGPM-AHPV---- 369
                        170       180       190       200       210       220       230       240
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089 498 eNPDQITEI--FDTIT-YSKGSSLVRMLEDFLGETTFRQAVTNYLNEYKYSTAETGNFfteIDKLE--LGYNVTEIMLtW 572
Cdd:PRK14015 370 -RPDSYIEInnFYTATvYEKGAEVIRMLHTLLGEEGFRKGMDLYFERHDGQAVTCEDF---VAAMEdaSGRDLSQFRR-W 444
                        250       260
                 ....*....|....*....|....*
gi 221379089 573 TVQMGLPVVTIEKVSDTE---YKLT 594
Cdd:PRK14015 445 YSQAGTPRVTVSDEYDAAagtYTLT 469
KLF9_13_N-like cd21975
Kruppel-like factor (KLF) 9, KLF13, KLF14, KLF16, and similar proteins; Kruppel/Krueppel-like ...
17-118 6.04e-04

Kruppel-like factor (KLF) 9, KLF13, KLF14, KLF16, and similar proteins; Kruppel/Krueppel-like transcription factors (KLFs) belong to a family of proteins, called the Specificity Protein (SP)/KLF family, characterized by a C-terminal DNA-binding domain of 81 amino acids consisting of three Kruppel-like C2H2 zinc fingers. These factors bind to a loose consensus motif, namely NNRCRCCYY (where N is any nucleotide; R is A/G, and Y is C/T), such as the recurring motifs in GC and GT boxes (5'-GGGGCGGGG-3' and 5-GGTGTGGGG-3') that are present in promoters and more distal regulatory elements of mammalian genes. Members of the KLF family can act as activators or repressors of transcription depending on cell and promoter context. KLFs regulate various cellular functions, such as proliferation, differentiation, and apoptosis, as well as the development and homeostasis of several types of tissue. KLF9, KLF10, KLF11, KLF13, KLF14, and KLF16 share a conserved alpha-helical motif AA/VXXL that mediates their binding to Sin3A and their activities as transcriptional repressors. In addition to the C-terminal DNA-binding domain, each KLF also has a unique N-terminal activation/repression domain that confers specificity and allows it to bind specifically to a certain partner, leading to distinct activities in vivo. This model represents the related N-terminal domains of KLF9, KLF13, KLF14, KLF16, and similar proteins.


Pssm-ID: 409240 [Multi-domain]  Cd Length: 163  Bit Score: 41.60  E-value: 6.04e-04
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089  17 TAFTVSTIVLAvqkANLKSDLRDAQEKLDLLEAGyTSTAAPTTASTANPGSTA--SPGSTAEPGSTAEPGSTAEPGSTAS 94
Cdd:cd21975   62 GLVTAAPHLLA---ANVLAPLRGPSVEGSSLESG-DADMGSDSDVAPASGAAAstSPESSSDAASSPSPLSLLHPGEAGL 137
                         90       100
                 ....*....|....*....|....
gi 221379089  95 PGSTVTPGSTASTSEPGTTASPEK 118
Cdd:cd21975  138 EPERPRPRVRRGVRRRGVTPAAKR 161
Epiglycanin_TR pfam05647
Tandem-repeating region of mucin, epiglycanin-like; The unusual mucin, epiglycanin, is ...
64-113 7.69e-03

Tandem-repeating region of mucin, epiglycanin-like; The unusual mucin, epiglycanin, is membrane-bound at the C-terminus but has a long region of this tandem-repeat at the N-terminus. It was the first mucin identified to be associated with the malignant behaviour of carcinoma cells. Mouse Muc21/epiglycanin is thought to be a highly glycosylated molecule, which makes it likely that its function is dependent on its glycoforms. Cells expressing Muc21 are significantly less adherent to each other and to extracellular matrix components than control cells, and this loss of adhesion is mediated by the TR portion of Muc21. This family also now contains the repeat that was the C. elegans protein of unknown function (DUF801).


Pssm-ID: 461702 [Multi-domain]  Cd Length: 68  Bit Score: 36.15  E-value: 7.69e-03
                          10        20        30        40        50
                  ....*....|....*....|....*....|....*....|....*....|.
gi 221379089   64 NPGSTASPGSTAePGSTAEPGSTAEPGSTAS-PGSTVTPGSTASTSEPGTT 113
Cdd:pfam05647  17 NTGSSTTSGGTS-TTSNTGSSTTSSGTSTATnTGSSETSSGSSTTSSTGTS 66
 
Name Accession Description Interval E-value
M1_APN-Q_like cd09601
Peptidase M1 aminopeptidase N catalytic domain family which includes aminopeptidase N (APN), ...
130-573 0e+00

Peptidase M1 aminopeptidase N catalytic domain family which includes aminopeptidase N (APN), aminopeptidase Q (APQ), tricorn interacting factor F3, and endoplasmic reticulum aminopeptidase 1 (ERAP1); This M1 peptidase family includes eukaryotic and bacterial members: the catalytic domains of aminopeptidase N (APN), aminopeptidase Q (APQ, laeverin), endoplasmic reticulum aminopeptidase 1 (ERAP1) as well as tricorn interacting factor F3. Aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease, preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is considered a marker of differentiation since it is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. ERAP1, also known as endoplasmic reticulum aminopeptidase associated with antigen processing (ERAAP), adipocyte derived leucine aminopeptidase (A-LAP), or aminopeptidase regulating tumor necrosis factor receptor I (THFRI) shedding (ARTS-1), associates with the closely related ER aminopeptidase ERAP2, for the final trimming of peptides within the ER for presentation by MHC class I molecules. ERAP1 is associated with ankylosing spondylitis (AS), an inflammatory arthritis that predominantly affects the spine. ERAP1 also aids in the shedding of membrane-bound cytokine receptors. The tricorn interacting factor F3, together with factors F1 and F2, degrades the tricorn protease products, producing free amino acids, thus completing the proteasomal degradation pathway. F3 is homologous to F2, but not F1, and shows a strong preference for glutamate in the P1' position. APQ, also known as laeverin, is specifically expressed in human embryo-derived extravillous trophoblasts (EVTs) that invade the uterus during early placentation. It cleaves the N-terminal amino acid of various peptides such as angiotensin III, endokinin C, and kisspeptin-10, all expressed in the placenta in large quantities. APN is a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs are also putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341064 [Multi-domain]  Cd Length: 442  Bit Score: 636.54  E-value: 0e+00
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089 130 THYDLYLFPNIETGEFSGQETITITVEEATDQIVLHSLNLNISSVSIMNTGSDTLEILETTVDAVREFLIFQLNEPLTKG 209
Cdd:cd09601    1 LHYDLTLTPDLENFTFSGSVTITLEVLEPTDTIVLHAKDLTITSASLTLKGGSGIIEVTVVTDEETEFLTITLDETLPPG 80
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089 210 RTVRLHIGFEGSMANKIVGLYSSSYVKEDETRKWIATSKFEPTYARQAFPCFDEPALKAEFTITLVHPsgEDYHALSNMN 289
Cdd:cd09601   81 ENYTLSIEFTGKLNDDLRGFYRSSYTDEDGETRYLAATQFEPTDARRAFPCFDEPAFKATFDITITHP--KGYTALSNMP 158
                        170       180       190       200       210       220       230       240
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089 290 -VDSSVSQGAFQEVTFAKSVPMSTYLACFIVSDFAYKQvSIDTKGIgetfSMSVYATPEQLDKVDLAVTIGKGVIEYYID 368
Cdd:cd09601  159 pVESTELEDGWKTTTFETTPPMSTYLVAFVVGDFEYIE-STTKSGV----PVRVYARPGKIEQGDFALEVAPKILDFYED 233
                        250       260       270       280       290       300       310       320
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089 369 YFQIAYPLPKLDMAAIPDFVSGAMEHWGLVTYRETSLLYDEATSSATNKQRIASVIAHEFAHMWFGNLVTMNWWNDLWLN 448
Cdd:cd09601  234 YFGIPYPLPKLDLVAIPDFAAGAMENWGLITYRETALLYDPKTSSASDKQRVAEVIAHELAHQWFGNLVTMKWWDDLWLN 313
                        330       340       350       360       370       380       390       400
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089 449 EGFASFVEYLGVDAVYPEWKMRDQFTVSTLHSVLTLDGTLGSHPIIQTVENPDQITEIFDTITYSKGSSLVRMLEDFLGE 528
Cdd:cd09601  314 EGFATYMEYLAVDKLFPEWNMWDQFVVDELQSALELDSLASSHPIEVPVESPSEISEIFDAISYSKGASVLRMLENFLGE 393
                        410       420       430       440
                 ....*....|....*....|....*....|....*....|....*...
gi 221379089 529 TTFRQAVTNYLNEYKYSTAETGNFFTEIDK---LELGYNVTEIMLTWT 573
Cdd:cd09601  394 EVFRKGLRKYLKKHAYGNATTDDLWEALQEasgESKPLDVKEIMDSWT 441
PepN COG0308
Aminopeptidase N, contains DUF3458 domain [Amino acid transport and metabolism];
120-715 4.06e-120

Aminopeptidase N, contains DUF3458 domain [Amino acid transport and metabolism];


Pssm-ID: 440077 [Multi-domain]  Cd Length: 609  Bit Score: 380.14  E-value: 4.06e-120
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089 120 DYRlPGTLKPTHYDLYLFPNIETGEFSGQETITITVEEA-TDQIVLHSLNLNISSVSIMNTgsdtleilETTVDAVREFL 198
Cdd:COG0308    9 AYR-PPGYDVTHYDLDLDLDPATTRLSGTATITFTATEApLDSLVLDLKGLEVTSVTVDGK--------PLDFTRDGERL 79
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089 199 IFQLNEPLTKGRTVRLHIGFEGSMANKIVGLYSSSYVKEDETrkWIATSkFEPTYARQAFPCFDEPALKAEFTITLVHPs 278
Cdd:COG0308   80 TITLPKPLAPGETFTLEIEYSGKPSNGGEGLYRSGDPPDGPP--YLYTQ-CEPEGARRWFPCFDHPDDKATFTLTVTVP- 155
                        170       180       190       200       210       220       230       240
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089 279 gEDYHALSNMN-VDSSVSQGAFQEVTFAKSVPMSTYLACFIVSDFAYKQVSIdTKGIgetfSMSVYATPEQLDKVDLAVT 357
Cdd:COG0308  156 -AGWVAVSNGNlVSETELGDGRTTWHWADTQPIPTYLFALAAGDYAVVEDTF-ASGV----PLRVYVRPGLADKAKEAFE 229
                        250       260       270       280       290       300       310       320
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089 358 IGKGVIEYYIDYFQIAYPLPKLDMAAIPDFVSGAMEHWGLVTYRETSLLYDEATSSatNKQRIASVIAHEFAHMWFGNLV 437
Cdd:COG0308  230 STKRMLDFFEELFGVPYPFDKYDQVAVPDFNFGAMENQGLVTFGEKVLADETATDA--DYERRESVIAHELAHQWFGNLV 307
                        330       340       350       360       370       380       390       400
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089 438 TMNWWNDLWLNEGFASFVEYLGVDAVYPE--WKMRDQFTVSTLHsvLTLDGTLGSHPIIqtVENPDQITEIFDTITYSKG 515
Cdd:COG0308  308 TCADWDDLWLNEGFATYMEQLFSEDLYGKdaADRIFVGALRSYA--FAEDAGPNAHPIR--PDDYPEIENFFDGIVYEKG 383
                        410       420       430       440       450       460       470       480
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089 516 SSLVRMLEDFLGETTFRQAVTNYLNEYKYSTAETGNFFTEIDKlELGYNVTEIMLTWTVQMGLPVVTIEKVSDTEYK--- 592
Cdd:COG0308  384 ALVLHMLRTLLGDEAFRAGLRLYFARHAGGNATTEDFLAALEE-ASGRDLSAFFDQWLYQAGLPTLEVEYEYDADGKvtl 462
                        490       500       510       520       530       540       550       560
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089 593 -LTQKRFlsnpndydadhepseFNYRWSIPITYFTSSDSVVQRLWFYHDQSEITVTVPAAVEWIKFNADQVGYYRVNYDT 671
Cdd:COG0308  463 tLRQTPP---------------RPHPFHIPLEVGLLGGKLTARTVLLDGEQTELVAKPDPVLLLRLDDELAFLLAHDSDP 527
                        570       580       590       600       610
                 ....*....|....*....|....*....|....*....|....*....|..
gi 221379089 672 --------DLWNDLADQLVVQPSAFGSVDRAhLLNDAFALADSTQLPYATAF 715
Cdd:COG0308  528 fnrwealqALWRDGEADYLDALRALADTDPA-VRAEALALLGSDQLALARAA 578
M1 cd09595
Peptidase M1 family includes the catalytic domains of aminopeptidase N and leukotriene A4 ...
130-552 6.61e-103

Peptidase M1 family includes the catalytic domains of aminopeptidase N and leukotriene A4 hydrolase; The model represents the catalytic domains of M1 peptidase family members including aminopeptidase N (APN) and leukotriene A4 hydrolase (LTA4H). All peptidases in this family bind a single catalytic zinc ion which is tetrahedrally co-ordinated by three amino acid ligands and a water molecule that forms the nucleophile upon activation during catalysis. APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and is present in a variety of human tissues and cell types. APN expression is dysregulated in many inflammatory diseases and is enhanced in numerous tumor cells, making it a lead target in the development of anti-cancer and anti-inflammatory drugs. LTA4H is a bifunctional enzyme, possessing an aminopeptidase as well as an epoxide hydrolase activity. The two activities occupy different, but overlapping sites. The activity and physiological relevance of the aminopeptidase in LTA4H is as yet unknown, while the epoxide hydrolase converts leukotriene A4 (LTA4) into leukotriene B4 (LTB4), a potent chemotaxin that is fundamental to the inflammatory response of mammals.


Pssm-ID: 341058 [Multi-domain]  Cd Length: 413  Bit Score: 327.86  E-value: 6.61e-103
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089 130 THYDLYLFPNIETGEFSGQETITITVEEATDQIVLHSLNLNISSVSImnTGSDTLEILETTVDavREFLifQLNEPLTKG 209
Cdd:cd09595    1 YHYDLDLDVDFTTKTLNGTETLTVDASQVGRELVLDLVGLTIHSVSV--NGAAVDFGEREHYD--GEKL--TIPGPKPPG 74
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089 210 RTVRLHIGFEGSMANKIVGLYSSSYVKEDETrkwIATSKFEPTYARQAFPCFDEPALKAEFTITLVHPSGeDYHALSNMN 289
Cdd:cd09595   75 QTFTVRISFEAKPSKNLLGWLWEQTAGKEKP---YLFTQFEATHARRIFPCIDHPAVKATFTVTITTPKK-DLLASNGAL 150
                        170       180       190       200       210       220       230       240
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089 290 VDSSVSQGAFQEVTFAKSVPMSTYLACFIVSDFAYKQVSIDTKGIGETfsmSVYATPEQLDKVDLAVTIGKGVIEYYIDY 369
Cdd:cd09595  151 VGEETGANGRKTYRFEDTPPIPTYLVAVVVGDLEFKYVTVKSQPRVGL---SVYSEPLQVDQAQYAFDATRAALAWFEDY 227
                        250       260       270       280       290       300       310       320
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089 370 FQIAYPLPKLDMAAIPDFVSGAMEHWGLVTYRETSLLYDEATssATNKQRIASVIAHEFAHMWFGNLVTMNWWNDLWLNE 449
Cdd:cd09595  228 FGGPYPLPKYDLLAVPDFNSGAMENPGLITFRTTYLLRSKVT--DTGARSIENVIAHELAHQWFGNLVTMRWWNDLWLNE 305
                        330       340       350       360       370       380       390       400
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089 450 GFASFVEYLGVDAVYPEWKmRDQFTVSTLHSVLTLDGTLGSHPIIQTVENPDQITEIFDTITYSKGSSLVRMLEDFLGET 529
Cdd:cd09595  306 GFAVYYENRIMDATFGTSS-RHLDQLSGSSDLNTEQLLEDSSPTSTPVRSPADPDVAYDGVTYAKGALVLRMLEELVGEE 384
                        410       420
                 ....*....|....*....|...
gi 221379089 530 TFRQAVTNYLNEYKYSTAETGNF 552
Cdd:cd09595  385 AFDKGVQAYFNRHKFKNATTDDF 407
Peptidase_M1 pfam01433
Peptidase family M1 domain; Members of this family are aminopeptidases. The members differ ...
355-572 3.83e-101

Peptidase family M1 domain; Members of this family are aminopeptidases. The members differ widely in specificity, hydrolysing acidic, basic or neutral N-terminal residues. This family includes leukotriene-A4 hydrolase, this enzyme also has an aminopeptidase activity.


Pssm-ID: 426262 [Multi-domain]  Cd Length: 219  Bit Score: 315.77  E-value: 3.83e-101
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089  355 AVTIGKGVIEYYIDYFQIAYPLPKLDMAAIPDFVSGAMEHWGLVTYRETSLLYDEATSSATNKQRIASVIAHEFAHMWFG 434
Cdd:pfam01433   2 ALEITVKLLEFYEDYFNIPYPLPKYDLVALPDFSAGAMENWGLITYRETLLLYDPGNSSTSDKQRVASVIAHELAHQWFG 81
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089  435 NLVTMNWWNDLWLNEGFASFVEYLGVDAVYPEWKMRDQFTVSTLHSVLTLDGTLGSHPIIQTVENPDQITEIFDTITYSK 514
Cdd:pfam01433  82 NLVTMKWWDDLWLNEGFATYMEYLGTDALFPEWNIWEQFLLDEVQNAMARDALDSSHPITQNVNDPSEIDDIFDAIPYEK 161
                         170       180       190       200       210
                  ....*....|....*....|....*....|....*....|....*....|....*...
gi 221379089  515 GSSLVRMLEDFLGETTFRQAVTNYLNEYKYSTAETGNFFTEIDKLELGYNVTEIMLTW 572
Cdd:pfam01433 162 GASVLRMLETLLGEEVFQKGLRSYLKKFQYGNATTEDLWDALSEASGPLDVDSFMDTW 219
ERAP1_C pfam11838
ERAP1-like C-terminal domain; This large domain is composed of 16 alpha helices organized as 8 ...
654-973 1.58e-97

ERAP1-like C-terminal domain; This large domain is composed of 16 alpha helices organized as 8 HEAT-like repeats. This domain forms a concave face that faces towards the active site of the peptidase.


Pssm-ID: 463368 [Multi-domain]  Cd Length: 316  Bit Score: 309.98  E-value: 1.58e-97
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089  654 WIKFNADQVGYYRVNYDTDLWNDLADQLvvQPSAFGSVDRAHLLNDAFALADSTQLPYATAFELTRYLDKETDYVPWSVA 733
Cdd:pfam11838   1 WVKLNADDTGYYRVNYDPESLAALLEQL--LSKVLSPLDRAGLIDDAFALARAGELSTSDALDLVLAYLNETDYVVWSAA 78
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089  734 ASRLTSLKRTLYYTSTYAKYKKYATALIEPIYTALTWT--VGEDHLDNRLRVTALSAACSLGLESCLTEAGEQFNAWLAK 811
Cdd:pfam11838  79 LSQLSTLRSLLSADPEYEALKAFLRKLLSPLAEKLGWEapPGESHLDRQLRALLLSAACSAGDPECVAEAKKLFDAWLDG 158
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089  812 PEDRPkADVRETVYYYGIQSvGSQEDWDAVWELFVNESDASEKSKLMYGLSAIQIPWILQRYIDLAWNEEYVRGQDYFTC 891
Cdd:pfam11838 159 DDAIP-PDLRWAVYCAAVAN-GGEAEWDALLERYRDTTSPSEKERALRALAATPDPELLQRALELALDSDEVRNQDLRAV 236
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089  892 LTYISANPVGESLVWDYVRENWQRLVDRFGLNErYLGNLIPSITARFSTQTKLEEMEQFFAKYPEAGAGTAARvRALETV 971
Cdd:pfam11838 237 IAGLASNPAGRDLAWDFVKENWDALVKRLGGGS-SLGRLVKGLTPSFSTEEELDEVEAFFADKDTPGLRRALA-QALETI 314

                  ..
gi 221379089  972 KN 973
Cdd:pfam11838 315 RR 316
M1_APN cd09602
Peptidase M1 family including aminopeptidase N catalytic domain; This model represents the ...
126-558 1.05e-94

Peptidase M1 family including aminopeptidase N catalytic domain; This model represents the catalytic domain of bacterial and eukaryotic aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease belonging to the M1 gluzincin family. APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and, in higher eukaryotes, is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation, thus considered a marker of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. APNs are also present in many pathogenic bacteria and represent potential drug targets. Some APNs have been used commercially, such as one from Lactococcus lactis used in the food industry. APN also serves as a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs have also been extensively studied as putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341065 [Multi-domain]  Cd Length: 440  Bit Score: 307.13  E-value: 1.05e-94
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089 126 TLKPTHYDLYLfpNIETGE--FSGQETITITVEEATDQIVLHSLNLNISSVSIMNTgsdtlEIleTTVDAVREFLIFqln 203
Cdd:cd09602   12 LISVVSYDLDL--DLTEGAetFRGTVTIRFTLREPGASLFLDFRGGEVKSVTLNGR-----PL--DPSAFDGERITL--- 79
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089 204 EPLTKGRTVRLHIGFEGSMANKIVGLYSssYVKEDETRKWIATSkFEPTYARQAFPCFDEPALKAEFTITLVHPsgEDYH 283
Cdd:cd09602   80 PGLLKAGENTVVVEFTAPYSSDGEGLHR--FVDPADGETYLYTL-FEPDDARRVFPCFDQPDLKATFTLTVTAP--ADWT 154
                        170       180       190       200       210       220       230       240
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089 284 ALSNMNVDSSVSQGAFQEVTFAKSVPMSTYLACFIVSDfaYKQVSIDTKGIgetfSMSVYA----TPEQLDKVDLAVTIG 359
Cdd:cd09602  155 VISNGPETSTEEAGGRKRWRFAETPPLSTYLFAFVAGP--YHRVEDEHDGI----PLGLYCreslAEYERDADEIFEVTK 228
                        250       260       270       280       290       300       310       320
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089 360 KGvIEYYIDYFQIAYPLPKLDMAAIPDFVSGAMEHWGLVTYRETSLLYDEATssATNKQRIASVIAHEFAHMWFGNLVTM 439
Cdd:cd09602  229 QG-LDFYEDYFGIPYPFGKYDQVFVPEFNFGAMENPGAVTFRESYLFREEPT--RAQRLRRANTILHEMAHMWFGDLVTM 305
                        330       340       350       360       370       380       390       400
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089 440 NWWNDLWLNEGFASFVEYLGVDAVYPE---WKmrdQFTVSTLHSVLTLDGTLGSHPIIQTVENPDQITEIFDTITYSKGS 516
Cdd:cd09602  306 KWWDDLWLNESFADFMAAKALAEATPFtdaWL---TFLLRRKPWAYRADQLPTTHPIAQDVPDLEAAGSNFDGITYAKGA 382
                        410       420       430       440
                 ....*....|....*....|....*....|....*....|..
gi 221379089 517 SLVRMLEDFLGETTFRQAVTNYLNEYKYSTAETGNFFTEIDK 558
Cdd:cd09602  383 SVLKQLVALVGEEAFRAGLREYFKKHAYGNATLDDLIAALDE 424
M1_APN_like cd09603
Peptidase M1 family similar to aminopeptidase N catalytic domain; This family contains mostly ...
130-572 5.87e-68

Peptidase M1 family similar to aminopeptidase N catalytic domain; This family contains mostly bacterial and some archaeal M1 peptidases with smilarity to the catalytic domain of aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease belonging to the M1 gluzincin family. APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and, in higher eukaryotes, is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation, thus considered a marker of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. APNs are also present in many pathogenic bacteria and represent potential drug targets. Some APNs have been used commercially, such as one from Lactococcus lactis used in the food industry. APN also serves as a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs have also been extensively studied as putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341066 [Multi-domain]  Cd Length: 410  Bit Score: 233.25  E-value: 5.87e-68
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089 130 THYDLYLFPNIETGEFSGQETITITVEEATDQIVLHSLNLNISSVsimntgsdtleiletTVDAVR--------EFLIFQ 201
Cdd:cd09603    4 LHYDLDLDYDPATKSLSGTATITFRATQDLDSLQLDLVGLTVSSV---------------TVDGVPaaffthdgDKLVIT 68
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089 202 LNEPLTKGRTVRLHIGFEGSManKIVGLYSSSYVKEDETRKWIATSKfEPTYARQAFPCFDEPALKAEFTITLVHPSGed 281
Cdd:cd09603   69 LPRPLAAGETFTVTVRYSGKP--RPAGYPPGDGGGWEEGDDGVWTAG-QPEGASTWFPCNDHPDDKATYDITVTVPAG-- 143
                        170       180       190       200       210       220       230       240
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089 282 YHALSN-MNVDSSVSQGAFQEVTFAKSVPMSTYLACFIVSDFAykqvsIDTKGIGETFSMSVYATPEQLDKVDLAVTIGK 360
Cdd:cd09603  144 LTVVSNgRLVSTTTNGGGTTTWHWKMDYPIATYLVTLAVGRYA-----VVEDGSGGGIPLRYYVPPGDAAKAKASFARTP 218
                        250       260       270       280       290       300       310       320
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089 361 GVIEYYIDYFqIAYPLPKLDMAAIPDFvSGAMEHWGLVTYRETSLLYDEATssatnkqriASVIAHEFAHMWFGNLVTMN 440
Cdd:cd09603  219 EMLDFFEELF-GPYPFEKYGQVVVPDL-GGGMEHQTATTYGNNFLNGDRGS---------ERLIAHELAHQWFGDSVTCA 287
                        330       340       350       360       370       380       390       400
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089 441 WWNDLWLNEGFASFVEYLgvdavYPEWKMRDQFTVSTLHSvlTLDGTLGSHPIIQTVENPDqitEIFDTITYSKGSSLVR 520
Cdd:cd09603  288 DWADIWLNEGFATYAEWL-----WSEHKGGADAYRAYLAG--QRQDYLNADPGPGRPPDPD---DLFDRDVYQKGALVLH 357
                        410       420       430       440       450
                 ....*....|....*....|....*....|....*....|....*....|..
gi 221379089 521 MLEDFLGETTFRQAVTNYLNEYKYSTAETGNFfteIDKLElgyNVTEIMLTW 572
Cdd:cd09603  358 MLRNLLGDEAFFAALRAYLARYAHGNVTTEDF---IAAAE---EVSGRDLTW 403
pepN_strep_liv TIGR02412
aminopeptidase N, Streptomyces lividans type; This family is a subset of the members of the ...
247-558 7.82e-62

aminopeptidase N, Streptomyces lividans type; This family is a subset of the members of the zinc metallopeptidase family M1 (pfam01433), with a single member characterized in Streptomyces lividans 66 and designated aminopeptidase N. The spectrum of activity may differ somewhat from the aminopeptidase N clade of E. coli and most other Proteobacteria, well separated phylogenetically within the M1 family. The M1 family also includes leukotriene A-4 hydrolase/aminopeptidase (with a bifunctional active site).


Pssm-ID: 274121 [Multi-domain]  Cd Length: 831  Bit Score: 226.21  E-value: 7.82e-62
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089  247 SKFEPTYARQAFPCFDEPALKAEFTITLVHPsgEDYHALSNMNVDSSVSQGAFQEVTFAKSVPMSTYLACFIVSDFaykq 326
Cdd:TIGR02412 122 TQFEPADARRVFAVFDQPDLKANFKFSVKAP--EDWTVISNSRETDVTPEPADRRWEFPETPKLSTYLTAVAAGPY---- 195
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089  327 VSIDTKGigETFSMSVYATP---EQLDKvDLAVTIGKGVIEYYIDYFQIAYPLPKLDMAAIPDFVSGAMEHWGLVTYRET 403
Cdd:TIGR02412 196 HSVQDES--RSYPLGIYARRslaQYLDA-DAIFTITRQGLAFFHRKFGYPYPFKKYDQIFVPEFNAGAMENAGCVTFAEN 272
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089  404 SLLYDEATSSAtnKQRIASVIAHEFAHMWFGNLVTMNWWNDLWLNEGFASFVEYLGVDAV--YPE-WKmrdQFTVSTLHS 480
Cdd:TIGR02412 273 FLHRAEATRAE--KENRAGVILHEMAHMWFGDLVTMRWWNDLWLNESFAEYMGTLASAEAteYTDaWT---TFAAQGKQW 347
                         250       260       270       280       290       300       310
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*...
gi 221379089  481 VLTLDGTLGSHPIIQTVENPDQITEIFDTITYSKGSSLVRMLEDFLGETTFRQAVTNYLNEYKYSTAETGNFFTEIDK 558
Cdd:TIGR02412 348 AYEADQLPTTHPIVADVADLADALSNFDGITYAKGASVLKQLVAWVGEEAFFAGVNAYFKRHAFGNATLDDLIDSLAK 425
Peptidase_M1_N pfam17900
Peptidase M1 N-terminal domain; This domain is found at the N-terminus of aminopeptidases from ...
128-314 5.85e-55

Peptidase M1 N-terminal domain; This domain is found at the N-terminus of aminopeptidases from the M1 family.


Pssm-ID: 465557 [Multi-domain]  Cd Length: 186  Bit Score: 188.71  E-value: 5.85e-55
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089  128 KPTHYDLYLFPNIETGEFSGQETITITVEEATDQIVLHSLNLNISSVSIMNTGSDTLEILETTVDAVR-EFLIFQLNEPL 206
Cdd:pfam17900   1 VPEHYDLDLKIDLKNFTFSGSVTITLQLNNATNVIVLHASDLTIRSISLSDEVTSDGVPADFTEDQKDgEKLTIVLPETL 80
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089  207 TKGRTVRLHIGFEGSMANKIVGLYSSSYVKEDEtRKWIATSKFEPTYARQAFPCFDEPALKAEFTITLVHPsgEDYHALS 286
Cdd:pfam17900  81 NQTGPYTLEIEYSGELNDSMTGFYRSTYTDNGE-KKVLVTTQFEPTDARSAFPCFDEPSVKATFTISIIHP--KDYTALS 157
                         170       180
                  ....*....|....*....|....*....
gi 221379089  287 NMNVDSSVSQGA-FQEVTFAKSVPMSTYL 314
Cdd:pfam17900 158 NMPVIASEPLENgWVITTFEQTPKMSTYL 186
M1_LTA4H cd09599
Peptidase M1 family including Leukotriene A4 hydrolase catalytic domain; This model represents ...
128-552 4.25e-38

Peptidase M1 family including Leukotriene A4 hydrolase catalytic domain; This model represents the N-terminal catalytic domain of leukotriene A4 hydrolase (LTA4H; E.C. 3.3.2.6) and the close homolog cold-active aminopeptidase (Colwellia psychrerythraea-type peptidase; ColAP), both members of the aminopeptidase M1 family. LTA4H is a bifunctional enzyme, possessing an aminopeptidase as well as an epoxide hydrolase activity. The two activities occupy different, but overlapping sites. The activity and physiological relevance of the aminopeptidase is poorly understood while the epoxide hydrolase converts leukotriene A4 (LTA4) into leukotriene B4 (LTB4), a potent chemotaxin that is fundamental to the inflammatory response of mammals. It accepts a variety of substrates, including some opioid, di- and tripeptides, as well as chromogenic aminoacyl-p-nitroanilide derivatives. The aminopeptidase activity of LTA4H is possibly involved in the processing of peptides related to inflammation and host defense. Kinetic analysis shows that LTA4H hydrolyzes arginyl tripeptides with high efficiency and specificity, indicating its function as an arginyl aminopeptidase. Thermodynamic characterization using different biophysical methods shows that structurally distinct inhibitors of the LTA4H occupy different regions of the binding site; while some (RB202, ARM1 and SC57461A) bind to the hydrophobic hydrolase side, both bestatin and captopril are located at the hydrophilic peptidase side. LTB4H overexpression is associated with different pathological conditions and diseases such as cystic fibrosis, coronary heart disease, sepsis, shock, connective tissue disease, and chronic obstructive pulmonary disease. It is also overexpressed in certain human cancers, and has been identified as a functionally important target for mediating anticancer properties of resveratrol, a well-known red wine polyphenolic compound with cancer chemopreventive activity.


Pssm-ID: 341062 [Multi-domain]  Cd Length: 442  Bit Score: 148.37  E-value: 4.25e-38
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089 128 KPTHYDLYLFPNIETGEFSGQETITITV-EEATDQIVLHSLNLNISSVSImntgsDTLEILETTVDAVREF----LIFQL 202
Cdd:cd09599   12 RTTHLDLDLTVDFDKKTISGSATLTLEVlQDGADELVLDTRDLDISSVTV-----NGGKELKFELGPRDPVlgsaLTITL 86
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089 203 NEPLTKGRTVRLHIGFEGSmaNKIVGLysssyvkedetrKWI-----ATSKF-------EPTYARQAFPCFDEPALKAEF 270
Cdd:cd09599   87 PSPLAKGDTFKVKIEYSTT--PQATAL------------QWLtpeqtAGKKHpylftqcQAIHARSLFPCQDTPSVKSTY 152
                        170       180       190       200       210       220       230       240
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089 271 TITLVHPSGedYHAL-SNMNVDSSVSQGaFQEVTFAKSVPMSTYLACFIVSDFAYKQvsidtkgIGEtfSMSVYATPEQL 349
Cdd:cd09599  153 SATVTVPKG--LTALmSALRTGEKEEAG-TGTYTFEQPVPIPSYLIAIAVGDLESRE-------IGP--RSGVWAEPSVV 220
                        250       260       270       280       290       300       310       320
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089 350 DKV-----DLAVTIGKGViEYYIDY----FQIAYpLPkldmaaiPDFVSGAMEHwGLVTYretsllydeATSS--ATNKQ 418
Cdd:cd09599  221 DAAaeefaDTEKFLKAAE-KLYGPYvwgrYDLLV-LP-------PSFPYGGMEN-PCLTF---------ATPTliAGDRS 281
                        330       340       350       360       370       380       390       400
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089 419 rIASVIAHEFAHMWFGNLVTMNWWNDLWLNEGFASFVEYLGVDAVYPEwKMRD---QFTVSTLH-SVLTLDGT--LGSHP 492
Cdd:cd09599  282 -LVDVIAHEIAHSWSGNLVTNANWEHFWLNEGFTVYLERRILERLYGE-EYRQfeaILGWKDLQeSIKEFGEDppYTLLV 359
                        410       420       430       440       450       460
                 ....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089 493 IIQTVENPDqitEIFDTITYSKGSSLVRMLEDFLGETTFRQAVTNYLNEYKYSTAETGNF 552
Cdd:cd09599  360 PDLKGVDPD---DAFSSVPYEKGFQFLYYLEQLGGREVFDPFLRAYFKKFAFQSIDTEDF 416
leuko_A4_hydro TIGR02411
leukotriene A-4 hydrolase/aminopeptidase; Members of this family represent a distinctive ...
109-632 1.29e-30

leukotriene A-4 hydrolase/aminopeptidase; Members of this family represent a distinctive subset within the zinc metallopeptidase family M1 (pfam01433). The majority of the members of pfam01433 are aminopeptidases, but the sequences in this family for which the function is known are leukotriene A-4 hydrolase. A dual epoxide hydrolase and aminopeptidase activity at the same active site is indicated. The physiological substrate for aminopeptidase activity is not known.


Pssm-ID: 274120 [Multi-domain]  Cd Length: 602  Bit Score: 128.74  E-value: 1.29e-30
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089  109 EPGTTASPEKIdyrlpgtlKPTHYDLYLFPNIETGEFSGQETITITVEEA-TDQIVLHSLNLNISSVSImnTGSDTLEIL 187
Cdd:TIGR02411   1 DPSSLSNYKDF--------RTSHTDLNLSVDFTKRKLSGSVTFTLKSLTDnLNKLVLDTSYLDIQKVTI--NGLPADFAI 70
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089  188 ETTVDAVREFLIFQLNEPLTKGRTVRLHIGFEGSmaNKIVGLyssSYVKEDETRKWIAT---SKFEPTYARQAFPCFDEP 264
Cdd:TIGR02411  71 GERKEPLGSPLTISLPIATSKNDEFVLNISFSTT--PKCTAL---QWLNPEQTSGKKHPylfSQCQAIHARSLFPCQDTP 145
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089  265 ALKAEFTITLVHPsgedYHALSNMNVDSSVSQGAFQEVtFAKSVPMSTYLACFIVSDFAYKQvsidtkgIGEtfSMSVYA 344
Cdd:TIGR02411 146 SVKSTYTAEVESP----LPVLMSGIRDGETSNDPGKYL-FKQKVPIPAYLIAIASGDLASAP-------IGP--RSTVYS 211
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089  345 TPEQLDKVDLavtigkgviEYYID---YFQIA------YPLPKLDMAAIPD-FVSGAMEHWGLvTYRETSLLydeatssA 414
Cdd:TIGR02411 212 EPEQLEKCQY---------EFENDtekFIKTAedlifpYEWGQYDLLVLPPsFPYGGMENPNL-TFATPTLI-------A 274
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089  415 TNKQRIaSVIAHEFAHMWFGNLVTMNWWNDLWLNEGFASFVEYLGVDAVYPEwKMRDQFTVSTL----HSVLTLDGTlgs 490
Cdd:TIGR02411 275 GDRSNV-DVIAHELAHSWSGNLVTNCSWEHFWLNEGWTVYLERRIIGRLYGE-KTRHFSALIGWgdlqESVKTLGET--- 349
                         410       420       430       440       450       460       470       480
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089  491 HPIIQTVEN-----PDqitEIFDTITYSKGSSLVRMLEDFLG-ETTFRQAVTNYLNEYKYSTAETGNFFT---------- 554
Cdd:TIGR02411 350 PEFTKLVVDlkdndPD---DAFSSVPYEKGFNFLFYLEQLLGgPAEFDPFLRHYFKKFAYKSLDTYQFKDalyeyfkdkk 426
                         490       500       510       520       530       540       550       560
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089  555 EIDKLE-LGYNvteimlTWTVQMGLPVVT---IEKVSDTEYKLTQKRflsnpNDYDADHEPSEFNyrwSIPITYFTSSDS 630
Cdd:TIGR02411 427 KVDKLDaVDWE------TWLYSPGMPPVKpnfDTTLADECYALADRW-----VDAAKADDLSSFN---AKDIKDFSSHQL 492

                  ..
gi 221379089  631 VV 632
Cdd:TIGR02411 493 VL 494
M1_APN cd09600
Peptidase M1 family, including aminopeptidase N catalytic domain; This model represents the ...
120-542 1.81e-25

Peptidase M1 family, including aminopeptidase N catalytic domain; This model represents the catalytic domain of aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease belonging to the M1 gluzincin family. It includes bacterial-type alanyl aminopeptidases as well as PfA-M1 aminopeptidase (Plasmodium falciparum-type). APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and, in higher eukaryotes, is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation, thus considered a marker of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. APNs are also present in many pathogenic bacteria and represent potential drug targets. Some APNs have been used commercially, such as one from Lactococcus lactis used in the food industry. APN also serves as a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs have also been extensively studied as putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341063 [Multi-domain]  Cd Length: 434  Bit Score: 110.68  E-value: 1.81e-25
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089 120 DYRLPGtlkpthydlYLFPNIE-TGEFSGQETI---TITVEEATDQ-----IVLHSLNLNISSVSIMNTgsdTLEILETT 190
Cdd:cd09600    1 DYKPPD---------FLIDHVDlDFDLDDDETIvtsRLRVRRNPDSgegapLVLDGEDLELLSVKIDGK---PLSPSDYT 68
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089 191 VDAvREFLIFQLNEPLTKGRTVRLHIGfegsmANK-IVGLYSSS--YVKEDET---RKwIatskfepTYarqaFPcfDEP 264
Cdd:cd09600   69 LDE-EGLTIKNVPDRFVLEIEVRINPA-----ANTsLEGLYKSGgiLCTQCEAegfRR-I-------TY----FP--DRP 128
                        170       180       190       200       210       220       230       240
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089 265 ALKAEFTITLVHPSgEDYHA-LSNMN-VDSSVSQGAFQEVTFAKSVPMSTYLACFIVSDFAYKQVSIDTKGiGETFSMSV 342
Cdd:cd09600  129 DVMSKFTVTIEADK-EKYPVlLSNGNlIEEGELPNGRHFAVWEDPFPKPSYLFALVAGDLGSVEDTFTTKS-GRKVKLRI 206
                        250       260       270       280       290       300       310       320
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089 343 YATPEQLDKVDLAV------------TIGkgvIEYYIDYFQIAyplpkldmaAIPDFVSGAMEHWGLVTYRETSLLYDEA 410
Cdd:cd09600  207 YVEPGNEDKCHHAMeslkkamkwdeeRFG---LEYDLDLFNIV---------AVDDFNMGAMENKGLNIFNSKYVLADPE 274
                        330       340       350       360       370       380       390       400
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089 411 TSSATNKQRIASVIAHEFAHMWFGNLVTMNWWNDLWLNEGFASFveylgvdavypewkmRDQ-FTvSTLHS--------V 481
Cdd:cd09600  275 TATDADYERIESVIAHEYFHNWTGNRVTCRDWFQLSLKEGLTVF---------------RDQeFS-ADMNSravkriedV 338
                        410       420       430       440       450       460       470
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|.
gi 221379089 482 LTL-------DGTLGSHPIiqtveNPDQITEI--FDTIT-YSKGSSLVRMLEDFLGETTFRQAVTNYLNEY 542
Cdd:cd09600  339 RRLrsaqfpeDAGPMAHPI-----RPDSYIEInnFYTVTvYEKGAEVIRMLHTLLGEEGFRKGMDLYFERH 404
M1_APN_like cd09604
Peptidase M1 family similar to aminopeptidase N catalytic domain; This family contains ...
133-558 1.22e-21

Peptidase M1 family similar to aminopeptidase N catalytic domain; This family contains bacterial M1 peptidases with smilarity to the catalytic domain of aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease belonging to the M1 gluzincin family. APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and, in higher eukaryotes, is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation, thus considered a marker of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. APNs are also present in many pathogenic bacteria and represent potential drug targets. Some APNs have been used commercially, such as one from Lactococcus lactis used in the food industry. APN also serves as a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs have also been extensively studied as putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341067 [Multi-domain]  Cd Length: 440  Bit Score: 98.89  E-value: 1.22e-21
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089 133 DLYLFPniETGEFSGQETITIT--VEEATDQIVLHsL---------------------------NLNISSVSImnTGSDT 183
Cdd:cd09604    4 DVTLDP--ETHTLTGKETITYTnnSPDTLDELYFH-LypnafkpgstmpardsriaklkgdepgGIDIDSVKV--NGKGL 78
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089 184 LEILETTVDAVRefliFQLNEPLTKGRTVRLHIGFEGSMANKIV--GLYSSSY----------VKEDEtrKWIAtskfEP 251
Cdd:cd09604   79 KLEVTLTITRLK----LALPLPLKPGESVTVEIDFTVKLPEQGGrfGYDGDEYnlaqwypklaVYDDG--GWNT----DP 148
                        170       180       190       200       210       220       230       240
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089 252 TYARQAFPCFDepalKAEFTITLVHPsgEDYH-ALSNMNVDSSVSQGAFQEVTF-AKSVPmstylacfivsDFA------ 323
Cdd:cd09604  149 YYGRGEFFYSD----FGDYDVTITVP--KNYVvAATGELQNPEEVLDGTKTWHFkAENVR-----------DFAwaaspd 211
                        250       260       270       280       290       300       310       320
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089 324 YKQVSIDTKGIgetfSMSVYATPEQLDKVDLAVTIGKGVIEYYIDYFqIAYPLPKLDMAAiPDFVSGAMEHWGLVTYret 403
Cdd:cd09604  212 FVVDAATVDGV----TVNVYYLPENAEAAERALEYAKDALEFFSEKF-GPYPYPELDVVQ-GPFGGGGMEYPGLVFI--- 282
                        330       340       350       360       370       380       390       400
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089 404 sllydeATSSATNKQRIASVIAHEFAHMWFGNLVTMNWWNDLWLNEGFASFVEYLGVDAVYPEWKMRDQFTVSTLHSVLT 483
Cdd:cd09604  283 ------GSRLYDPKRSLEGVVVHEIAHQWFYGIVGNDERREPWLDEGLATYAESLYLEEKYGKEAADELLGRRYYRAYAR 356
                        410       420       430       440       450       460       470
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*.
gi 221379089 484 LDGTlgshPIIQTV-ENPDQITEifDTITYSKGSSLVRMLEDFLGETTFRQAVTNYLNEYKYSTAETGNFFTEIDK 558
Cdd:cd09604  357 GPGG----PINLPLdTFPDGSYY--SNAVYSKGALFLEELREELGDEAFDKALREYYRRYKFKHPTPEDFFRTAEE 426
pepN PRK14015
aminopeptidase N; Provisional
364-594 1.69e-15

aminopeptidase N; Provisional


Pssm-ID: 237585 [Multi-domain]  Cd Length: 875  Bit Score: 81.33  E-value: 1.69e-15
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089 364 EYYIDYFQIAyplpkldmaAIPDFVSGAMEHWGL-------VtyretslLYDEATssATNK--QRIASVIAHEFAHMWFG 434
Cdd:PRK14015 249 EYDLDIFMIV---------AVDDFNMGAMENKGLnifnskyV-------LADPET--ATDAdyERIESVIAHEYFHNWTG 310
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089 435 NLVTMNWWNDLWLNEGFASFveylgvdavypewkmRDQ-FTvSTLHS--------VLTLD--------GTLgSHPIiqtv 497
Cdd:PRK14015 311 NRVTCRDWFQLSLKEGLTVF---------------RDQeFS-ADLGSravkriedVRVLRaaqfaedaGPM-AHPV---- 369
                        170       180       190       200       210       220       230       240
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089 498 eNPDQITEI--FDTIT-YSKGSSLVRMLEDFLGETTFRQAVTNYLNEYKYSTAETGNFfteIDKLE--LGYNVTEIMLtW 572
Cdd:PRK14015 370 -RPDSYIEInnFYTATvYEKGAEVIRMLHTLLGEEGFRKGMDLYFERHDGQAVTCEDF---VAAMEdaSGRDLSQFRR-W 444
                        250       260
                 ....*....|....*....|....*
gi 221379089 573 TVQMGLPVVTIEKVSDTE---YKLT 594
Cdd:PRK14015 445 YSQAGTPRVTVSDEYDAAagtYTLT 469
M1_like_TAF2 cd09839
TATA binding protein (TBP) associated factor 2; This family includes TATA binding protein (TBP) ...
237-454 1.81e-05

TATA binding protein (TBP) associated factor 2; This family includes TATA binding protein (TBP) associated factor 2 (TAF2, TBP-associated factor TAFII150, transcription initiation factor TFIID subunit 2, RNA polymerase II TBP-associated factor subunit B), and has homology to the M1 gluzincin family. TAF2 is part of the TFIID multidomain subunit complex essential for transcription of most protein-encoded genes by RNA polymerase II. TAF2 is known to interact with the initiator element (Inr) found at the transcription start site of many genes, thus possibly playing a key role in promoter binding as well as start-site selection. Image analysis has shown TAF2 to form a complex with TAF1 and TBP, inferring its role in promoter recognition. Peptidases in the M1 family bind a single catalytic zinc ion which is tetrahedrally co-ordinated by three amino acid ligands and a water molecule that forms the nucleophile on activation during catalysis. TAF2, however, lacks these active site residues.


Pssm-ID: 341074 [Multi-domain]  Cd Length: 531  Bit Score: 48.38  E-value: 1.81e-05
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089 237 EDETRKWIA--TSKFEPTYARQAFPCFDEP--------------ALKAEFTITLVHPSGEDYHALSNMNVDSS----VSQ 296
Cdd:cd09839  157 GGDKRYPHVytTNSPLPGSARCWFPCVDSLwerctweleitvprTLGDAGRPPLAGSKEDEDDDDLTEEDKELemvvVCS 236
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089 297 GAFQE------------VTFAKSVPMStylACFI---------VSDFAYKQVSIDTKGIGETFSMSVYATPEQLDkvDLA 355
Cdd:cd09839  237 GDLVEqvvhpedpskktFSFSLSNPTS---AQHIgfavgpfeiVPLPEFRESEEDDKLGSSAVEVTGFCLPGRLE--ELR 311
                        170       180       190       200       210       220       230       240
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089 356 VTIGK--GVIEYYIDYFqIAYPLP--KL---DMAAiPDFVSGAmehwGLVTYrETSLLYD----EATSSATNKqriasvI 424
Cdd:cd09839  312 NTCSFlhKAMDFFEEEY-GSYPFSsyKQvfvDDLP-EDVSSFA----SLSIC-SSRLLYPpdiiDQAYETRRK------L 378
                        250       260       270
                 ....*....|....*....|....*....|
gi 221379089 425 AHEFAHMWFGNLVTMNWWNDLWLNEGFASF 454
Cdd:cd09839  379 AHALASQWFGINIIPKTWSDTWLVIGIAGY 408
GluZincin cd09594
Gluzincin Peptidase family (thermolysin-like proteinases, TLPs) which includes peptidases M1, ...
423-458 4.92e-04

Gluzincin Peptidase family (thermolysin-like proteinases, TLPs) which includes peptidases M1, M2, M3, M4, M13, M32 and M36 (fungalysins); The Gluzincin family (thermolysin-like peptidases or TLPs) includes several zinc-dependent metallopeptidases such as M1, M2, M3, M4, M13, M32, M36 peptidases (MEROPS classification), which contain the HEXXH motif as part of their active site. Peptidases in this family bind a single catalytic zinc ion which is tetrahedrally co-ordinated by three amino acid ligands and a water molecule that forms the nucleophile on activation during catalysis. The M1 family includes aminopeptidase N (APN) and leukotriene A4 hydrolase (LTA4H). APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and is present in a variety of human tissues and cell types. LTA4H is a bifunctional enzyme, possessing an aminopeptidase as well as an epoxide hydrolase activity such that the two activities occupy different, but overlapping sites. The M3_like peptidases include the M2_ACE, M3 or neurolysin-like family (subfamilies M3B_PepF and M3A) and M32_Taq peptidases. The M2 peptidase angiotensin converting enzyme (ACE, EC 3.4.15.1) catalyzes the conversion of decapeptide angiotensin I to the potent vasopressor octapeptide angiotensin II. ACE is a key component of the renin-angiotensin system that regulates blood pressure, thus ACE inhibitors are important for the treatment of hypertension. M3A includes thimet oligopeptidase (TOP; endopeptidase 3.4.24.15), neurolysin (3.4.24.16), and the mitochondrial intermediate peptidase; and M3B includes oligopeptidase F. The M32 family includes eukaryotic enzymes from protozoa Trypanosoma cruzi, a causative agent of Chagas' disease, and from Leishmania major, a parasite that causes leishmaniasis, making these enzymes attractive targets for drug development. The M4 family includes secreted protease thermolysin (EC 3.4.24.27), pseudolysin, aureolysin, and neutral protease as well as bacillolysin (EC 3.4.24.28) that degrade extracellular proteins and peptides for bacterial nutrition, especially prior to sporulation. Thermolysin is widely used as a nonspecific protease to obtain fragments for peptide sequencing as well as in production of the artificial sweetener aspartame. The M13 family includes neprilysin (EC 3.4.24.11) and endothelin-converting enzyme I (ECE-1, EC 3.4.24.71), which fulfill a broad range of physiological roles due to the greater variation in the S2' subsite allowing substrate specificity and are prime therapeutic targets for selective inhibition. The peptidase M36 fungalysin family includes endopeptidases from pathogenic fungi. Fungalysin hydrolyzes extracellular matrix proteins such as elastin and keratin. Aspergillus fumigatus causes the pulmonary disease aspergillosis by invading the lungs of immuno-compromised animals and secreting fungalysin that possibly breaks down proteinaceous structural barriers.


Pssm-ID: 341057 [Multi-domain]  Cd Length: 105  Bit Score: 40.54  E-value: 4.92e-04
                         10        20        30
                 ....*....|....*....|....*....|....*..
gi 221379089 423 VIAHEFAHMWFGNLVT-MNWWNDLWLNEGFASFVEYL 458
Cdd:cd09594   68 VLAHELTHAFTGQFSNlMYSWSSGWLNEGISDYFGGL 104
KLF9_13_N-like cd21975
Kruppel-like factor (KLF) 9, KLF13, KLF14, KLF16, and similar proteins; Kruppel/Krueppel-like ...
17-118 6.04e-04

Kruppel-like factor (KLF) 9, KLF13, KLF14, KLF16, and similar proteins; Kruppel/Krueppel-like transcription factors (KLFs) belong to a family of proteins, called the Specificity Protein (SP)/KLF family, characterized by a C-terminal DNA-binding domain of 81 amino acids consisting of three Kruppel-like C2H2 zinc fingers. These factors bind to a loose consensus motif, namely NNRCRCCYY (where N is any nucleotide; R is A/G, and Y is C/T), such as the recurring motifs in GC and GT boxes (5'-GGGGCGGGG-3' and 5-GGTGTGGGG-3') that are present in promoters and more distal regulatory elements of mammalian genes. Members of the KLF family can act as activators or repressors of transcription depending on cell and promoter context. KLFs regulate various cellular functions, such as proliferation, differentiation, and apoptosis, as well as the development and homeostasis of several types of tissue. KLF9, KLF10, KLF11, KLF13, KLF14, and KLF16 share a conserved alpha-helical motif AA/VXXL that mediates their binding to Sin3A and their activities as transcriptional repressors. In addition to the C-terminal DNA-binding domain, each KLF also has a unique N-terminal activation/repression domain that confers specificity and allows it to bind specifically to a certain partner, leading to distinct activities in vivo. This model represents the related N-terminal domains of KLF9, KLF13, KLF14, KLF16, and similar proteins.


Pssm-ID: 409240 [Multi-domain]  Cd Length: 163  Bit Score: 41.60  E-value: 6.04e-04
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221379089  17 TAFTVSTIVLAvqkANLKSDLRDAQEKLDLLEAGyTSTAAPTTASTANPGSTA--SPGSTAEPGSTAEPGSTAEPGSTAS 94
Cdd:cd21975   62 GLVTAAPHLLA---ANVLAPLRGPSVEGSSLESG-DADMGSDSDVAPASGAAAstSPESSSDAASSPSPLSLLHPGEAGL 137
                         90       100
                 ....*....|....*....|....
gi 221379089  95 PGSTVTPGSTASTSEPGTTASPEK 118
Cdd:cd21975  138 EPERPRPRVRRGVRRRGVTPAAKR 161
Epiglycanin_TR pfam05647
Tandem-repeating region of mucin, epiglycanin-like; The unusual mucin, epiglycanin, is ...
64-113 7.69e-03

Tandem-repeating region of mucin, epiglycanin-like; The unusual mucin, epiglycanin, is membrane-bound at the C-terminus but has a long region of this tandem-repeat at the N-terminus. It was the first mucin identified to be associated with the malignant behaviour of carcinoma cells. Mouse Muc21/epiglycanin is thought to be a highly glycosylated molecule, which makes it likely that its function is dependent on its glycoforms. Cells expressing Muc21 are significantly less adherent to each other and to extracellular matrix components than control cells, and this loss of adhesion is mediated by the TR portion of Muc21. This family also now contains the repeat that was the C. elegans protein of unknown function (DUF801).


Pssm-ID: 461702 [Multi-domain]  Cd Length: 68  Bit Score: 36.15  E-value: 7.69e-03
                          10        20        30        40        50
                  ....*....|....*....|....*....|....*....|....*....|.
gi 221379089   64 NPGSTASPGSTAePGSTAEPGSTAEPGSTAS-PGSTVTPGSTASTSEPGTT 113
Cdd:pfam05647  17 NTGSSTTSGGTS-TTSNTGSSTTSSGTSTATnTGSSETSSGSSTTSSTGTS 66
 
Blast search parameters
Data Source: Precalculated data, version = cdd.v.3.21
Preset Options:Database: CDSEARCH/cdd   Low complexity filter: no  Composition Based Adjustment: yes   E-value threshold: 0.01

References:

  • Wang J et al. (2023), "The conserved domain database in 2023", Nucleic Acids Res.51(D)384-8.
  • Lu S et al. (2020), "The conserved domain database in 2020", Nucleic Acids Res.48(D)265-8.
  • Marchler-Bauer A et al. (2017), "CDD/SPARCLE: functional classification of proteins via subfamily domain architectures.", Nucleic Acids Res.45(D)200-3.
Help | Disclaimer | Write to the Help Desk
NCBI | NLM | NIH